Investigational drug · Phase 3
TPN171H
Also called: Simmerafil
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Erectile Dysfunction.
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
14
Any phase or sponsor naming "TPN171H"
First trial start
2024
Apr 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TPN171H", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erectile Dysfunction
Approved drugs for the same conditions: Erectile dysfunction
Largest trials
Live from ClinicalTrials.gov: studies naming "TPN171H" as an intervention, largest first.
- Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.Pivotal-lookingCompleted
Vigonvita Life SciencesIndustry
NCT05188989 · 765 participants · Start Dec 31, 2021 · Primary completion Feb 14, 2023
Drug: TPN171H 2.5mg group; TPN171H 5mg group and 2 more · For: Erectile Dysfunction
Sites: Hefei, China; Wuhu, China; Beijing, China · 49 sites in all
- Long-term Safety of TPN171H Tablet in Erectile Dysfunction.Pivotal-lookingCompleted
Vigonvita Life SciencesIndustry
NCT06301854 · 472 participants · Start Apr 12, 2024 · Primary completion Jun 5, 2025
Drug: TPN171H · For: Erectile Dysfunction
Sites: Hefei, China; Beijing, China; Guangzhou, China · 34 sites in all
- Efficacy and Safety of TPN171H in the Patients With Erectile DysfunctionPivotal-lookingCompleted
Vigonvita Life SciencesIndustry
NCT04479917 · 255 participants · Start Jul 23, 2020 · Primary completion Jul 26, 2021
Drug: TPN171H; placebo · For: Erectile Dysfunction
Sites: Hefei, China; Beijing, China; Fuzhou, China · 12 sites in all
- Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile DysfunctionCompleted
Vigonvita Life SciencesIndustry
NCT05388825 · 84 participants · Start Aug 1, 2022 · Primary completion Jan 4, 2023
Drug: TPN171H 2.5mg; TPN171H 5mg and 3 more · For: Erectile Dysfunction
Sites: Hefei, China; Beijing, China; Fuzhou, China · 8 sites in all
Vigonvita Life SciencesIndustry
NCT04483115 · 60 participants · Start Nov 16, 2020 · Primary completion Jun 29, 2022
Drug: TPN171H; Placebo and 1 more · For: Pulmonary Arterial Hypertension
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 9 sites in all
Vigonvita Life SciencesIndustry
NCT05750355 · 32 participants · Start Oct 10, 2022 · Primary completion Dec 7, 2022
Drug: TPN171H 10 mg Group; TPN171H 30 mg Group and 2 more · For: Healthy Subjects
Sites: Shanghai, China
Vigonvita Life SciencesIndustry
NCT06090123 · 24 participants · Start Jan 1, 2020 · Primary completion Apr 27, 2020
Drug: TPN171H; Itraconazole and 1 more · For: Erectile Dysfunction
Sites: Shanghai, China
Vigonvita Life SciencesIndustry
NCT05185011 · 24 participants · Start Dec 16, 2021 · Primary completion Feb 6, 2022
Drug: TPN171H · For: Erectile Dysfunction; Pulmonary Arterial Hypertension
Sites: Changchun, China
- A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male SubjectsCompleted
Vigonvita Life SciencesIndustry
NCT05316428 · 19 participants · Start Feb 24, 2022 · Primary completion Apr 2, 2022
Drug: TPN171H tablet plus alcohol; TPN171H tablet · For: Alcohol; Phosphodiesterase Inhibitor; Erectile Dysfunction
Sites: Shanghai, China
- Effect of TPN171H on SpermatogenesisCompleted
Vigonvita Life SciencesIndustry
NCT05585931 · 18 participants · Start Nov 15, 2022 · Primary completion Dec 16, 2022
Drug: TPN171H 10mg; TPN171H Placebo · For: Erectile Dysfunction
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial.
Zhou YP, Qiu LH, Ma W, et al. · Signal Transduct Target Ther 2026
- TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats.
Zhao C, Hu L, He X, et al. · Vascul Pharmacol 2022
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.
Qian H, Chen Q, Liang L, et al. · Drug Des Devel Ther 2021
Also in development for Erectile Dysfunction
- TestofenPhase 32 trials
RDC Clinical Pty Ltd · Long Covid19, Erectile Dysfunction
- DTT106Phase 31 trial
EMS · Prostatic Hyperplasia, Benign, Erectile Dysfunction
- HGP1201Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- HIP2602Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- HPP2602-1Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- HPP2602-2Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- LIB-01Phase 21 trial
Dicot AB · Erectile Dysfunction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.